Internation No PCT/FR2004/002422

		10.71.1200	,					
A. CLASSII IPC 7	FICATION OF SUBJECT MATTER A61K38/00 C07K14/00 A61P35/0	0						
According to International Patent Classification (IPC) or to both national classification and IPC								
B. FIELDS								
Minimum documentation searched (classification system followed by classification symbols) IPC 7 CO7K								
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched								
	ata base consulted during the international search (name of data bas							
EPO-In	ternal, BIOSIS, WPI Data, CHEM ABS D	ata, INSPEC, Sequence	Search					
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT							
Category °	Citation of document, with indication, where appropriate, of the rela	evant passages	Relevant to claim No.					
Υ	KAWAGUCHI MICHIYA ET AL: "A nove synthetic Arg-Gly-Asp-containing cyclo(-RGDfdbdV-) is the potent is of angiogenesis" BIOCHEMICAL AND BIOPHYSICAL RESEAT COMMUNICATIONS, vol. 288, no. 3, 2 November 2001 (2001-11-02), page 711-717, XP002274582 & ISSN: 0006-291X whole document, in particular on right col. and table 1, and page	peptide nhibitor ARCH ges page 713	1-12					
X Furt	her documents are listed in the continuation of box C.	X Patent family members are listed	i in annex.					
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is clied to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but		later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.						
1	0 February 2005	18/02/2005						
Name and	mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni,	Authorized officer						

Internation No PCT/FR2004/002422

		PCT/FR2004/002422		
	Itlen) DOCUMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.		
Y	KUMAR C CHANDRA: "Integrin alphavbeta3 as a therapeutic target for blocking tumor-induced angiogenesis." CURRENT DRUG TARGETS, vol. 4, no. 2, February 2003 (2003-02), pages 123-131, XP0009027835 & ISSN: 1389-4501 the whole document	1-12		
Υ	WESTLIN W F: "Integrins as targets of angiogenesis inhibition." CANCER JOURNAL (SUDBURY, MASS.) 2001 NOV-DEC, vol. 7 Suppl 3, November 2001 (2001-11), pages S139-S143, XP0009027919 ISSN: 1528-9117 the whole document	1-12		
Y	WO 00/49038 A (SCHUBERT, ULRICH; HENKLEIN, PETER; WRAY, VICTOR) 24 August 2000 (2000-08-24) Some peptides in the application contain part of the claimed peptide motifs as in claim 1, for instance SEQ ID N°3 shows 100% identity with SEQ ID N°12 over 16aa overlap the whole document	1-4		
A .	RUEGG C ET AL: "Vascular integrins: Pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis." CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 60, no. 6, June 2003 (2003-06), pages 1135-1157, XP0001180259 & ISSN: 1420-682X in particular pages 1143-45 the whole document	1-12		
A	COSTANTINI P ET AL: "Mitochondrion as a novel target of anticancer chemotherapy." JOURNAL OF THE NATIONAL CANCER INSTITUTE. 5 JUL 2000, vol. 92, no. 13, 5 July 2000 (2000-07-05), pages 1042-1053, XP0009008236 ISSN: 0027-8874 the whole document -/	8		

Interrenal Application No PCT/FR2004/002422

		PCT/FR2004/002422			
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT					
alegory °	Ctation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
A	SCHRAA ASTRID J ET AL: "Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting." JOURNAL OF CONTROLLED RELEASE: OFFICIAL JOURNAL OF THE CONTROLLED RELEASE SOCIETY. 4 OCT 2002, vol. 83, no. 2, 4 October 2002 (2002-10-04), pages 241-251, XP0004383634 ISSN: 0168-3659 the whole document	1-12			
A	WO 01/92542 A (ICH PRODUCTIONS LTD; HART STEPHEN LEWIS (GB)) 6 December 2001 (2001-12-06) en particulier revendications 12-18	1-12			
A	HAUBNER R ET AL: "STEREOISOMERIC PEPTIDE LIBRARIES AND PEPTIDOMIMETICS FOR DESIGNING SELECTIVE INHIBITORS OF THE ALPHAVBETA3 INTEGRIN FOR A NEW CANCER THERAPY" ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, VERLAG CHEMIE. WEINHEIM, DE, vol. 36, 1997, pages 1375-1389, XP001008836 ISSN: 0570-0833 the whole document	1-12			
P,X	WO 2004/031768 A (THERAPTOSIS S.A; JACOTOT, ETIENNE; LECOEUR, HERVE; REBOUILLAT, DOMINIQ) 15 April 2004 (2004-04-15) peptide sequence 5 is 96% identical to SEQ ID N°7, and 100% identical to SEQ ID N°1 the whole document	1 .			

armation on patent family members

International Application No
PCT/FR2004/002422

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0049038	A	24-08-2000	CA DE DE WO EP JP	2356390 A1 19908752 A1 19908766 A1 0049038 A2 1155035 A2 2002540768 T	17-02-2003 31-08-2000 31-08-2000 24-08-2000 21-11-2001 03-12-2002
WO 0192542	A	06-12-2001	AU CA EP WO WO JP US	5865901 A 6046701 A 2410419 A1 1285081 A2 0192542 A2 0192543 A2 2003534804 T 2004014217 A1	11-12-2001 11-12-2001 06-12-2001 26-02-2003 06-12-2001 06-12-2001 25-11-2003 22-01-2004
WO 2004031768	Α	15-04-2004	WO	2004031768 A2	15-04-2004